source
- Roche inks $1 billion deal with Dualitas to screen 300,000 bispecific combos for immunology and inflammationRoche has agreed to pay Dualitas Therapeutics an upfront $36.5 million as part of a broader agreement that could be worth up to $1 billion. The collaboration will use Dualitas’s DualScreen platfor…
- Novo and Orbis strike up to $1.4 billion partnership to develop oral peptide macrocycles for cardiometabolic diseaseNovo Pharmaceuticals has entered a partnership with fellow Danish firm Orbis Medicines that could be worth as much as $1.4 billion. The agreement includes upfront payments, downstream payouts and r…BioPharma Dive · 1mo agoDealPositive